Diagnosis and treatment of prostatitis in Canada

• Published in: Urology (Ridgewood, N.J.) Vol. 52; no. 5; pp. 797 - 802
• Main Authors: Nickel, J.Curtis, Nigro, Mark, Valiquette, Luc, Anderson, Peter, Patrick, Allan, Mahoney, John, Buckley, Roger, Corcos, Jacques, Hosking, Denis
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.11.1998; Elsevier Science
• Subjects: Biological and medical sciences; Canada; Data Collection; Humans; Male; Medical sciences; Nephrology. Urinary tract diseases; Practice Patterns, Physicians; Primary Health Care; Prostatitis - diagnosis; Prostatitis - therapy; Urinary system involvement in other diseases. Miscellaneous; Urinary tract. Prostate gland; Urology; Canada; North America; America; Human; Sulfanilamide derivatives; Drug combination; Urinary system disease; Sulfonamide; Prostate disease; Trimethoprim; Male; Chemotherapy; Chronic; Sulfamethoxazole; Treatment; Prostatitis; Diagnosis; Male genital diseases; Public health
• ISSN: 0090-4295; 1527-9995
• DOI: 10.1016/S0090-4295(98)00297-0

Objectives. There is a general consensus among physicians that the present management of chronic prostatitis is dismal. We undertook a survey of Canadian primary care physicians (PCPs) and urologists to determine the degree and source of frustration and to analyze present practice patterns in this disease. Methods. Five thousand PCPs and all 545 Canadian urologists were asked to complete a comprehensive computer-assisted telephone survey that explored practice characteristics, attitudes, and diagnostic and treatment strategies in the management of prostatitis. Randomization of attribute banks, adherence to questionnaire routing, validation by on-site monitoring, and possible bias were addressed. Results. Completed interviews were obtained from 10% of PCPs and 28% of urologists. PCPs see on average 3.5 (median 2) patients with prostatitis per month and urologists see on average 21.8 (median 11) patients with prostatitis per month. All physicians experience significantly more frustration in treating prostatitis than they do in treating patients with benign prostatic hyperplasia (BPH) and prostate cancer, and they perceive that prostatitis affects patients’ quality of life significantly more than BPH and almost as much as prostate cancer. The degree of frustration and unhappiness in dealing with prostatitis is driven by a lack of confidence and comfort in their ability to accurately diagnose and subsequently rationalize treatment. Most PCPs and urologists continue to employ steps in addition to history and physical examination to establish a diagnosis but only a few PCPs and a third of urologists use specific lower urinary tract cultures. Physicians tend to use trimethoprim or trimethoprim-sulfamethoxazole (TMP-SMX) or a fluoroquinolone as their usual first line therapy for chronic prostatitis. The most commonly used therapeutic strategy (40%) for chronic prostatitis was TMP-SMX as first line therapy and a fluoroquinolone as second line therapy. Conclusions. There is widespread frustration, discomfort, and lack of confidence in both PCPs’ and urologists’ perceived ability to manage prostatitis. Physicians have expressed a desire for a better understanding of this disease, simpler and clearer diagnostic guidelines, and more rational treatment strategies.